Zimmer Biomet Holdings, Inc. (ZBH) Up 4.8% — Do I Make This Trade Today?
Zimmer Biomet Holdings, Inc. (ZBH) posted a decisive gain in today's session, climbing 4.76% and adding $3.79 to close at $83.37 on the NYSE. The move marks a meaningful step in the right direction for a stock that has faced persistent pressure over the past several months. ZBH still sits approximately 23.0% below its 52-week high of $108.29, reached on August 26, 2025 — a gap that underscores how much ground the stock has to recover, but also how much room exists for a sustained rebound if the current momentum holds.
Volume came in at approximately 2.40 million shares, running modestly above the 90-day average of roughly 2.30 million. The slightly elevated turnover suggests today's move attracted a broader base of participation than a typical session. That combination of above-average volume alongside a clean price gain adds credibility to the day's advance.
Why Zimmer Biomet Holdings, Inc. Price is Moving Higher
The primary catalyst behind ZBH's move is a stronger-than-expected Q1 2026 earnings report released on May 5, 2026. Zimmer Biomet posted EPS of $1.98 against a consensus estimate of $1.919 — a beat of $0.061 — while revenue reached $2.15 billion, topping expectations of $2.12 billion by approximately 1.4%. Year-over-year revenue growth of 4.2% was driven by outperformance in the knees and hips segments, which climbed 6.1% YoY, reflecting continued recovery in elective procedure volumes post-COVID. Profit margins expanded meaningfully to 18.2% from 16.8% a year earlier, while net income rose 12% to $412 million — a combination of cost discipline and higher throughput that investors had been waiting to see.
What amplified the market's reaction was management's decision to raise full-year 2026 guidance, lifting EPS expectations to $8.45–$8.65 from the prior range of $8.30–$8.50. That upward revision carried added weight given the backdrop of gains in the company's robotic surgery platform and a 5% organic revenue growth outlook for the year. The medtech sector more broadly is catching a tailwind from aging demographics — a structural demand driver that positions orthopedic device makers like Zimmer Biomet favorably as procedure volumes continue to normalize and expand. With Q2 2026 earnings now on the calendar for August 4 and analyst consensus EPS estimates sitting at $2.122 for that quarter, the setup for continued fundamental progress is clearly in focus for investors.
From a valuation standpoint, a forward P/E of 20.64 looks increasingly reasonable relative to the earnings trajectory being laid out by management. After months of underperformance, the stock's breakout above prior resistance levels on post-earnings momentum signals that sentiment may be shifting. Investors who have been waiting on the sidelines for a confirmation of improving fundamentals now have a data point worth paying attention to.
What is the Zimmer Biomet Holdings, Inc. Rating - Should I Buy?
Weiss Ratings assigns ZBH a C rating. Current recommendation is Hold. That assessment reflects a mixed picture — one where genuine operational progress is visible but not yet consistent enough across all dimensions to warrant a more aggressive stance.
On the positive side, revenue growth of 9.30% earns a Good Growth Index — a respectable clip for a large-cap medical device company operating in a market where procedure volumes, pricing dynamics, and competitive intensity all shape the top line. A profit margin of 9.05% pairs with that growth figure to earn a Good Efficiency Index, reflecting that Zimmer Biomet is generating real earnings power as it scales — not an easy accomplishment for a capital-intensive manufacturer navigating a complex supply chain and hospital procurement environment. The Excellent Solvency Index adds further reassurance, pointing to a balance sheet capable of supporting continued investment in platforms like its robotic surgery offering without putting the company in a precarious leverage position.
Where the picture softens is in the return and volatility profiles. An ROE of 6.06% is the underlying driver of the Good Efficiency label at the top level, but it also signals that Zimmer Biomet has not yet converted its asset base into the kind of equity returns that typically attract premium valuations in the Health Care sector — especially compared to peers with stronger capital efficiency. The Weak Total Return Index and Weak Volatility Index together flag that the stock has delivered inconsistent performance for shareholders while subjecting them to meaningful price swings along the way. The 23% gap to the 52-week high is itself a testament to that volatility dynamic.
Within the Health Care sector, Zimmer Biomet is on par with Intuitive Surgical, Inc. (ISRG, C) and Stryker Corporation (SYK, C), while ranking ahead of UnitedHealth Group Incorporated (UNH, C-) and Abbott Laboratories (ABT, C-). That relative positioning suggests Zimmer Biomet is neither a laggard nor a standout within its peer group — fitting for a Hold that warrants attention but calls for patience before committing additional capital.
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. (ZBH) is a Health Care company operating within the Health Care Equipment and Services industry, focused on designing, manufacturing, and distributing musculoskeletal healthcare products and related surgical solutions. The company's core franchise is built around reconstructive implants for the knee and hip — the same segments that drove outperformance in its most recent earnings report — along with extremities, trauma, spine, and dental products. These offerings are deployed in hospitals and ambulatory surgical centers worldwide, placing Zimmer Biomet at the center of elective surgical procedures that are structurally supported by aging global populations and rising rates of joint disease.
Beyond its implant portfolio, Zimmer Biomet has been investing meaningfully in its robotic surgery platform, which management has identified as a key competitive differentiator and growth driver for the years ahead. Robotic-assisted surgery systems enable surgeons to perform procedures with greater precision and consistency, and adoption has been accelerating across the orthopedic market. The company's platform is designed to work in conjunction with its implant portfolio — creating an integrated ecosystem that deepens customer relationships with surgeons and hospital systems and supports long-term revenue retention.
Zimmer Biomet's competitive position rests on decades of clinical experience, an extensive intellectual property portfolio, and strong relationships within the surgical community. The company operates across more than 25 countries, with manufacturing facilities and distribution networks built to serve both developed and emerging markets. Its diversified product mix across joint reconstruction, surgical enablement, and biologics gives it exposure to several layers of the orthopedic care continuum — an advantage that becomes particularly meaningful as healthcare systems increasingly look to consolidate vendor relationships and improve procedural outcomes under value-based care frameworks.
Investor Outlook
Zimmer Biomet Holdings, Inc. (ZBH) carries a Weiss Rating of C (Hold), reflecting a company with improving fundamentals that has not yet translated those gains into consistent shareholder returns. Investors should watch the August 4 Q2 2026 earnings report closely — management's raised guidance sets a higher bar to clear, and execution on robotic surgery adoption and organic revenue growth will be the key variables to track. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--